You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIpratropium bromide
Accession NumberDB00332  (APRD00537)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]
Structure
Thumb
Synonyms
(endo,syn)-(±)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
3α-hydroxy-8-isopropyl-1αH,5αH-tropanium bromide (±)-tropate
8-Isopropylnoratropine methobromide
Bromure d'ipratropium
Bromuro de ipratropio
Ipratropii bromidum
Ipratropium bromide (anhydrous)
Ipratropium bromide anhydrous
Ipratropiumbromid
N-Isopropylnoratropinium bromomethylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atroventspray, metered21 ug/1nasalBoehringer Ingelheim Pharmaceuticals, Inc.1996-01-01Not applicableUs
Atroventspray, metered21 ug/1nasalPhysicians Total Care, Inc.2006-03-31Not applicableUs
Atroventspray, metered42 ug/1nasalBoehringer Ingelheim Pharmaceuticals, Inc.1996-01-01Not applicableUs
Atroventsolution250 mcginhalationBoehringer Ingelheim (Canada) Ltd Ltee1988-12-312007-10-11Canada
Atrovent HFAmetered-dose aerosol20 mcginhalationBoehringer Ingelheim (Canada) Ltd Ltee2004-03-24Not applicableCanada
Atrovent HFAaerosol, metered17 ug/1respiratory (inhalation)Boehringer Ingelheim Pharmaceuticals Inc.2005-05-01Not applicableUs
Atrovent Nasal Aerosol 20mcg/aemaerosol20 mcginhalation; nasalBoehringer Ingelheim (Canada) Ltd Ltee1989-12-311999-08-09Canada
Atrovent Nasal Spray - 21mcg/aemmetered-dose aerosol; liquid21 mcgnasalBoehringer Ingelheim (Canada) Ltd Ltee1995-12-31Not applicableCanada
Atrovent Nasal Spray - 42mcg/aemmetered-dose aerosol; liquid42 mcgnasalBoehringer Ingelheim (Canada) Ltd Ltee1996-02-02Not applicableCanada
Atrovent Udv 125mcg/mlsolution125 mcginhalation; oralBoehringer Ingelheim (Canada) Ltd Ltee1993-12-312008-09-18Canada
Atrovent Udv Sol Inh 250mcg/mlsolution250 mcginhalationBoehringer Ingelheim (Canada) Ltd Ltee1992-12-312008-04-16Canada
Atroventhfaaerosol, metered17 ug/1respiratory (inhalation)Physicians Total Care, Inc.2006-01-20Not applicableUs
Dom-ipratropiumliquid0.3 mginhalation; nasalDominion Pharmacal1999-09-15Not applicableCanada
Dom-ipratropium 125 Mcg/mlliquid125 mcginhalationDominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (1 Ml)liquid250 mcginhalationDominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (2 Ml)liquid250 mcginhalationDominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (20 Ml)liquid250 mcginhalationDominion PharmacalNot applicableNot applicableCanada
Ipratropiumliquid0.30 mginhalationPharmel IncNot applicableNot applicableCanada
Ipraventsolution0.03 %nasalAa Pharma Inc2002-12-03Not applicableCanada
Ipraventsolution0.06 %nasalAa Pharma Inc2002-12-03Not applicableCanada
Mylan-ipratropium Solutionsolution0.25 mginhalationMylan Pharmaceuticals Ulc1998-12-04Not applicableCanada
Novo-ipramide - Liq 0.25mg/mlsolution.25 mginhalationNovopharm Limited1996-12-312015-10-26Canada
Nu-ipratropium Plastic Ampules 250 Mcg/mlsolution250 mcginhalationNu Pharm Inc1997-12-032012-09-04Canada
Penta-ipratropium Bromideliquid0.25 mginhalationPentapharm Ltd.Not applicableNot applicableCanada
PHL-ipratropiumsolution125 mcginhalationPharmel Inc1998-02-17Not applicableCanada
PHL-ipratropium - 20mlsolution250 mcginhalationPharmel Inc1998-02-172009-10-26Canada
PHL-ipratropium - 1ml Polynebsolution250 mcginhalationPharmel Inc1998-02-17Not applicableCanada
PHL-ipratropium - 2ml Polynebsolution250 mcginhalationPharmel Inc1998-02-17Not applicableCanada
PMS-ipratropiumsolution250 mcginhalationPharmascience Inc1997-07-15Not applicableCanada
PMS-ipratropiumsolution125 mcginhalationPharmascience Inc1997-10-29Not applicableCanada
PMS-ipratropiumliquid0.30 mginhalationPharmascience Inc1999-04-15Not applicableCanada
PMS-ipratropium (2ml Unit Dose)solution250 mcginhalationPharmascience Inc1997-10-29Not applicableCanada
PMS-ipratropium (1ml Unit Dose)solution250 mcginhalationPharmascience Inc1997-10-29Not applicableCanada
Ratio-ipratropiummetered-dose pump21 mcgnasalRatiopharm Inc Division Of Teva Canada Limited1999-09-282008-08-01Canada
Ratio-ipratropium Inhalation Solutionsolution250 mcginhalation; nasalRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-07-17Canada
Ratio-ipratropium Udvsolution250 mcginhalationTeva Canada Limited1995-12-31Not applicableCanada
Ratio-ipratropium Udvsolution125 mcginhalationTeva Canada Limited1997-12-04Not applicableCanada
Teva-ipratropium Sterinebssolution0.025 %inhalationTeva Canada Limited1998-03-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ipravent Solution - Inh 250mcg/mlsolution250 mcginhalationApotex Inc1994-12-31Not applicableCanada
Apo-ipravent Sterulessolution0.025 %inhalationApotex Inc1998-07-09Not applicableCanada
Apo-ipravent Sterulessolution125 mcginhalationApotex Inc2001-08-28Not applicableCanada
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Preferred Pharmaceuticals, Inc2013-02-22Not applicableUs
Ipratropium Bromidespray, metered21 ug/1nasalBausch & Lomb Incorporated2003-03-31Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Physicians Total Care, Inc.1998-12-03Not applicableUs
Ipratropium Bromidespray21 ug/1nasalRoxane Laboratories, Inc2003-11-05Not applicableUs
Ipratropium Bromidespray, metered42 ug/1nasalREMEDYREPACK INC.2013-06-12Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Cardinal Health1997-01-10Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Watson Laboratories, Inc.2011-03-01Not applicableUs
Ipratropium Bromidespray, metered42 ug/1nasalBausch & Lomb Incorporated2003-03-31Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Preferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
Ipratropium Bromidespray42 ug/1nasalRoxane Laboratories, Inc2003-11-15Not applicableUs
Ipratropium Bromidespray, metered42 ug/1nasalPhysicians Total Care, Inc.2004-04-12Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)REMEDYREPACK INC.2013-06-04Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)St Marys Medical Park Pharmacy2014-01-30Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Sandoz Inc.2011-09-01Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Rebel Distributors Corp2011-03-01Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Ritedose Pharmaceuticals, LLC2011-02-01Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Mylan Pharmaceuticals, Inc.2010-11-09Not applicableUs
Ipratropium Bromidespray, metered21 ug/1nasalPhysicians Total Care, Inc.2007-01-24Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)A S Medication Solutions2011-02-01Not applicableUs
Ipratropium Bromidespray42 ug/1nasalREMEDYREPACK INC.2013-07-16Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Proficient Rx LP2011-03-01Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Rebel Distributors Corp2005-05-09Not applicableUs
Ipratropium Bromidespray, metered42 ug/1nasalRebel Distributors Corp2003-03-31Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Nephron Pharmaceuticals Corporation2001-09-27Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Cardinal Health2001-09-27Not applicableUs
Ipratropium Bromidesolution.5 mg/2.5mLrespiratory (inhalation)Aidarex Pharmaceuticals LLC2011-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AeroventTeva
ApoventApotex Inc.
AtronaseBoehringer Ingelheim
IpraxaIvax
IpventCipla Medpro
RhinoventBoehringer Ingelheim
RinatecBoehringer Ingelheim
RinovagosValeas
Brand mixtures
NameLabellerIngredients
Apo-salvent-ipravent SterulesApotex Inc
Combivent Inhalation AerosolBoehringer Ingelheim (Canada) Ltd Ltee
Combivent RespimatBoehringer Ingelheim Pharmaceuticals Inc.
Combivent UdvBoehringer Ingelheim (Canada) Ltd Ltee
DuonebMylan Specialty
Duovent UdvBoehringer Ingelheim (Canada) Ltd Ltee
IpramolIvax Pharmaceuticals Incorporated
Ipratropium Bromide and Albuterol SulfateTeva Pharmaceuticals USA Inc
Ratio-ipra Sal UdvTeva Canada Limited
Teva-combo SterinebsTeva Canada Limited
Salts
Name/CASStructureProperties
Ipratropium bromide hydrate
66985-17-9
Thumb
  • InChI Key: KEWHKYJURDBRMN-ZEODDXGYSA-M
  • Monoisotopic Mass: 429.151472
  • Average Mass: 430.383
DBSALT000208
Categories
UNIIVJV4X1P2Z1
CAS number22254-24-6
WeightAverage: 412.361
Monoisotopic: 411.140906478
Chemical FormulaC20H30BrNO3
InChI KeyInChIKey=LHLMOSXCXGLMMN-VVQPYUEFSA-M
InChI
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21+;
IUPAC Name
(1R,3R,5S,8R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide
SMILES
[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Tropane alkaloid
  • Beta-hydroxy acid
  • N-alkylpyrrolidine
  • Piperidine
  • Hydroxy acid
  • Quaternary ammonium salt
  • Pyrrolidine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic bromide salt
  • Organic salt
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
PharmacodynamicsIpratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
Mechanism of actionIpratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.
Related Articles
AbsorptionInhalation (local)-minimal; Nasal-rapid and minimal
Volume of distribution
  • 4.6 L/kg
Protein bindingMinimally (0 to 9% in vitro) bound to plasma albumin and α1-acid glycoproteins
Metabolism

Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; α-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH3OH-group. These metabolites appear to be inactive.

SubstrateEnzymesProduct
Ipratropium bromide
Not Available
N-isopropylnortropium methobromideDetails
Ipratropium bromide
Not Available
Phenylacetic acid-N-isopropylnortropine-ester methobromideDetails
Route of eliminationPrimarily eliminated renally via active secretion.
Half life2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t1/2 α) and terminal elimination-phase half-life (t1/2 β) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.
Clearance
  • 2.3 L/min (total clearance of active ingredient)
ToxicityLD50=1001mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9425
Blood Brain Barrier+0.8883
Caco-2 permeable+0.6619
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor INon-inhibitor0.8489
P-glycoprotein inhibitor IINon-inhibitor0.5964
Renal organic cation transporterInhibitor0.6651
CYP450 2C9 substrateNon-substrate0.7214
CYP450 2D6 substrateNon-substrate0.7637
CYP450 3A4 substrateSubstrate0.6657
CYP450 1A2 substrateNon-inhibitor0.8412
CYP450 2C9 inhibitorNon-inhibitor0.9118
CYP450 2D6 inhibitorNon-inhibitor0.8915
CYP450 2C19 inhibitorNon-inhibitor0.8783
CYP450 3A4 inhibitorNon-inhibitor0.9396
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.8979
BiodegradationReady biodegradable0.5154
Rat acute toxicity2.7983 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis mid atlantic llc
  • Bausch and lomb pharmaceuticals inc
  • Cobalt laboratories inc
  • Dey lp
  • Holopack international corp
  • Landela pharmaceutical
  • Nephron corp
  • Novex pharma
  • Pharmascience inc
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Bausch and lomb inc
Packagers
Dosage forms
FormRouteStrength
Solutioninhalation250 mcg
Spray, meterednasal21 ug/1
Spray, meterednasal42 ug/1
Aerosol, meteredrespiratory (inhalation)17 ug/1
Metered-dose aerosolinhalation20 mcg
Aerosolinhalation; nasal20 mcg
Metered-dose aerosol; liquidnasal21 mcg
Metered-dose aerosol; liquidnasal42 mcg
Solutioninhalation; oral125 mcg
Metered-dose aerosolinhalation; oral
Spray, meteredrespiratory (inhalation)
Solutioninhalation
Liquidinhalation; nasal0.3 mg
Liquidinhalation125 mcg
Liquidinhalation250 mcg
Solutioninhalation; oral
Solutionrespiratory (inhalation).5 mg/2.5mL
Spraynasal21 ug/1
Spraynasal42 ug/1
Solutionrespiratory (inhalation)
Solutionnasal0.03 %
Solutionnasal0.06 %
Solutioninhalation0.25 mg
Solutioninhalation.25 mg
Liquidinhalation0.25 mg
Liquidinhalation0.30 mg
Metered-dose pumpnasal21 mcg
Solutioninhalation; nasal250 mcg
Solutioninhalation125 mcg
Solutioninhalation0.025 %
Prices
Unit descriptionCostUnit
Atrovent HFA 17 mcg/act Aerosol 12.9 gm Inhaler143.59USD inhaler
Ipratropium bromide powder100.06USD g
Atrovent 0.03% Solution 30ml Nasal Spray96.95USD bottle
Atrovent 0.06% Solution 15ml Nasal Spray84.68USD bottle
Ipratropium Bromide 0.03% Solution 30ml Bottle53.82USD bottle
Ipratropium Bromide 0.06% Solution 15ml Bottle46.14USD bottle
Ipratropium Bromide 0.02% Solution Each Box Contains Twenty-Five 2.5ml Vials45.86USD box
Atrovent hfa inhaler11.89USD g
Atrovent 0.06% spray5.33USD ml
Atrovent 0.03% spray3.11USD ml
Ipratropium 0.06% spray2.96USD ml
Ipratropium 0.03% spray1.73USD ml
Atrovent 0.03 % Spray1.04USD ml
Apo-Ipravent 250 mcg/ml Solution0.58USD ml
Mylan-Ipratropium 250 mcg/ml Solution0.58USD ml
Novo-Ipramide 250 mcg/ml Solution0.58USD ml
Pms-Ipratropium 0.03 % Spray0.58USD ml
Pms-Ipratropium 250 mcg/ml Solution0.58USD ml
Atrovent Hfa 20 mcg/dose Metered Dose Aerosol0.1USD metered dose aerosol
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2151383 No2005-02-082013-12-06Canada
US5766573 No1992-11-282009-11-28Us
US5964416 No1996-10-042016-10-04Us
US6149054 No1996-12-192016-12-19Us
US6176442 No1996-10-042016-10-04Us
US6453795 No1996-12-052016-12-05Us
US6632842 No2001-12-282021-12-28Us
US6726124 No1996-10-042016-10-04Us
US6739333 No2000-05-262020-05-26Us
US6846413 No1998-08-282018-08-28Us
US6977042 No1998-08-282018-08-28Us
US6983743 No2000-05-262020-05-26Us
US6988496 No2000-02-232020-02-23Us
US7104470 No1996-10-042016-10-04Us
US7246615 No1996-05-312016-05-31Us
US7284474 No2004-08-262024-08-26Us
US7396341 No2006-10-102026-10-10Us
US7802568 No1999-02-262019-02-26Us
US7837235 No2008-03-132028-03-13Us
US7896264 No2005-05-262025-05-26Us
US7988001 No2001-08-042021-08-04Us
US8474447 No2010-01-172030-01-17Us
US8733341 No2009-12-162029-12-16Us
US9027967 No2007-03-312027-03-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231.5U.S. Patent 3,505,337
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000701 mg/mLALOGPS
logP0.21ALOGPS
logP-1.8ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity105.9 m3·mol-1ChemAxon
Polarizability37.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference
  1. Abdine HH, Belala F, and Al-Badra AA. (2003). Ipratropium bromide: Methods of chemical and biochemical synthesis. In H.G. Brittain (Ed.). Profiles of drug substances, excipients and related methodology (pp. 85-99). Amsterdam, Netherlands: Elsevier Academic Press.
General References
  1. Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y: [Antiallergic asthma effect of ipatropium bromide (Sch 1000) in dogs (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Oct;73(7):785-91. [PubMed:145994 ]
External Links
ATC CodesR01AX03R03AL02R03AL01R03BB01
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (88.1 KB)
MSDSDownload (72.7 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.
AbirateroneThe metabolism of Ipratropium bromide can be decreased when combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Ipratropium bromide.
AclidiniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Aclidinium.
AlfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alphacetylmethadol.
AmbenoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ambenonium.
AmiodaroneThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Anisotropine Methylbromide.
AprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Aprepitant.
ArtemetherThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.
AtazanavirThe metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.
AtropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atropine.
BenactyzineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium bromide.
BetaxololThe metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bexarotene.
BezitramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.
BoceprevirThe metabolism of Ipratropium bromide can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.
Botulinum Toxin Type AIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.
BuprenorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.
BupropionThe metabolism of Ipratropium bromide can be decreased when combined with Bupropion.
ButorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.
CarbamazepineThe metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Carfentanil.
CelecoxibThe metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Ceritinib.
ChloroquineThe metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Chlorphenoxamine.
ChlorpromazineThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.
CholecalciferolThe metabolism of Ipratropium bromide can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.
CimetropiumIpratropium bromide may increase the anticholinergic activities of Cimetropium.
CinacalcetThe metabolism of Ipratropium bromide can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Ipratropium bromide can be decreased when combined with Clemastine.
ClobazamThe metabolism of Ipratropium bromide can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.
ClotrimazoleThe metabolism of Ipratropium bromide can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Ipratropium bromide can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Ipratropium bromide can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Ipratropium bromide can be decreased when combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.
ConivaptanThe serum concentration of Ipratropium bromide can be increased when it is combined with Conivaptan.
CoumaphosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Coumaphos.
CrizotinibThe metabolism of Ipratropium bromide can be decreased when combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Cyclopentolate.
CyclosporineThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.
DarifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.
DarunavirThe serum concentration of Ipratropium bromide can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.
DecamethoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Decamethonium.
DeferasiroxThe serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ipratropium bromide can be decreased when combined with Delavirdine.
DemecariumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Demecarium.
DesipramineThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.
DexamethasoneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dexetimide.
DextromoramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Dichlorvos.
DicyclomineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.
DiltiazemThe metabolism of Ipratropium bromide can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Ipratropium bromide can be decreased when combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.
DonepezilThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Donepezil.
DoxycyclineThe metabolism of Ipratropium bromide can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with DPDPE.
DronabinolIpratropium bromide may increase the tachycardic activities of Dronabinol.
DronedaroneThe metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.
EchothiophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Edrophonium.
EfavirenzThe serum concentration of Ipratropium bromide can be decreased when it is combined with Efavirenz.
EliglustatThe metabolism of Ipratropium bromide can be decreased when combined with Eliglustat.
EluxadolineIpratropium bromide may increase the constipating activities of Eluxadoline.
EnzalutamideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Ipratropium bromide can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Ipratropium bromide can be decreased when it is combined with Eslicarbazepine acetate.
EthopropazineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.
EtorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etorphine.
EtravirineThe serum concentration of Ipratropium bromide can be decreased when it is combined with Etravirine.
FentanylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.
FenthionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.
FluconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Fluconazole.
FluoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.
FluvoxamineThe metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ipratropium bromide can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Ipratropium bromide can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Ipratropium bromide can be increased when it is combined with Fusidic Acid.
GalantamineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Gallamine Triethiodide.
Ginkgo bilobaThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Ipratropium bromide.
GlycopyrroniumIpratropium bromide may increase the anticholinergic activities of Glycopyrronium.
HaloperidolThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.
HydrocodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.
HydromorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hyoscyamine.
IdelalisibThe serum concentration of Ipratropium bromide can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Ipratropium bromide can be decreased when combined with Imatinib.
ImipramineThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.
IndinavirThe metabolism of Ipratropium bromide can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Ipratropium bromide can be decreased when combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.
IsoniazidThe metabolism of Ipratropium bromide can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Ipratropium bromide can be decreased when combined with Isradipine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Ipratropium bromide.
ItraconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Ipratropium bromide can be increased when it is combined with Ivacaftor.
KetobemidoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ketobemidone.
KetoconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Ketoconazole.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.
LofentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Lofentanil.
LopinavirThe metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Ipratropium bromide can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Ipratropium bromide can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Ipratropium bromide can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.
MalathionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Malathion.
MecamylamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.
MefloquineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.
MemantineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Memantine.
MethadoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadone.
MethadoneThe metabolism of Ipratropium bromide can be decreased when combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methantheline.
MethotrimeprazineThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.
MetixeneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.
MetoprololThe metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.
MianserinMianserin may increase the anticholinergic activities of Ipratropium bromide.
MifepristoneThe metabolism of Ipratropium bromide can be decreased when combined with Mifepristone.
MinaprineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.
MirabegronThe metabolism of Ipratropium bromide can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Ipratropium bromide can be decreased when it is combined with Modafinil.
MorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with N-butylscopolammonium bromide.
NabiloneIpratropium bromide may increase the tachycardic activities of Nabilone.
NafcillinThe serum concentration of Ipratropium bromide can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.
NefazodoneThe metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine.
NetupitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ipratropium bromide can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.
NormethadoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with NVA237.
OlaparibThe metabolism of Ipratropium bromide can be decreased when combined with Olaparib.
OpiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.
OsimertinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Osimertinib.
OxybutyninThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ipratropium bromide.
PalbociclibThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.
PancuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.
PanobinostatThe metabolism of Ipratropium bromide can be decreased when combined with Panobinostat.
ParoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.
PentazocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.
PentobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentolinium.
PethidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.
PhenobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Ipratropium bromide can be increased when combined with Phenytoin.
PhysostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Physostigmine.
PipecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Ipratropium bromide.
PosaconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.
Potassium ChlorideIpratropium bromide may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Ipratropium bromide.
PrimidoneThe metabolism of Ipratropium bromide can be increased when combined with Primidone.
ProcyclidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Procyclidine.
PromazineThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.
PropanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.
PyridostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Pyridostigmine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.
QuinidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Quinidine.
QuinineThe metabolism of Ipratropium bromide can be decreased when combined with Quinine.
RamosetronIpratropium bromide may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Ipratropium bromide can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.
RifabutinThe metabolism of Ipratropium bromide can be increased when combined with Rifabutin.
RifampicinThe metabolism of Ipratropium bromide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Ipratropium bromide can be increased when combined with Rifapentine.
RitonavirThe metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Rivastigmine.
RolapitantThe metabolism of Ipratropium bromide can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Ipratropium bromide can be decreased when combined with Ropinirole.
SaquinavirThe metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.
SertralineThe metabolism of Ipratropium bromide can be decreased when combined with Sertraline.
SildenafilThe metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ipratropium bromide can be increased when it is combined with Simeprevir.
SolifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Solifenacin.
St. John's WortThe serum concentration of Ipratropium bromide can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Ipratropium bromide can be increased when it is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.
SulfisoxazoleThe metabolism of Ipratropium bromide can be decreased when combined with Sulfisoxazole.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.
TacrineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tapentadol.
TelaprevirThe metabolism of Ipratropium bromide can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Telithromycin.
TerbinafineThe metabolism of Ipratropium bromide can be decreased when combined with Terbinafine.
ThioridazineThe metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.
TiclopidineThe metabolism of Ipratropium bromide can be decreased when combined with Ticlopidine.
TiotropiumIpratropium bromide may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Ipratropium bromide.
TipranavirThe metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.
TocilizumabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.
TolterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tolterodine.
TopiramateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.
TranylcypromineThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.
TrichlorfonThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.
TrimethaphanThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan.
TropicamideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropicamide.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ipratropium bromide.
TubocurarineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Ipratropium bromide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Umeclidinium.
VecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.
VenlafaxineThe metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.
VoriconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Voriconazole.
ZiprasidoneThe metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:15